Table 1. Patient, Lesion, and Procedural Characteristics and Medications.
| Characteristics | 1-Month DAPT (n = 1500) | 12-Month DAPT (n = 1509) |
|---|---|---|
| Age, mean (SD), y | 68.1 (10.9) | 69.1 (10.4) |
| ≥75, No. (%) | 448 (29.9) | 499 (33.1) |
| Men, No. (%) | 1183 (78.9) | 1154 (76.5) |
| Women, No. (%) | 317 (21.1) | 355 (23.5) |
| BMI, mean (SD) | 24.4 (3.5) | 24.2 (3.5) |
| <25, No. (%) | 879 (58.6) | 936 (62.0) |
| Acute coronary syndrome, No. (%)a | 565 (37.7) | 583 (38.6) |
| ST-segment elevation myocardial infarction | 291 (19.4) | 270 (17.9) |
| Non–ST-segment elevation myocardial infarction | 81 (5.4) | 99 (6.6) |
| Unstable anginab | 193 (12.9) | 214 (14.2) |
| Stable coronary artery disease, No. (%) | 935 (62.3) | 926 (61.4) |
| Prior percutaneous coronary intervention, No. (%) | 503 (33.5) | 529 (35.1) |
| Prior first-generation drug-eluting stents, No. (%) | 65 (4.3) | 47 (3.1) |
| Prior coronary artery bypass graft surgery, No. (%) | 17 (1.1) | 42 (2.8) |
| Prior myocardial infarction, No. (%) | 207 (13.8) | 199 (13.2) |
| Prior ischemic or hemorrhagic stroke, No. (%) | 81 (5.4) | 105 (7.0) |
| Comorbidities, No. (%) | ||
| Hypertension | 1105 (73.7) | 1116 (74.0) |
| Hyperlipidemia | 1116 (74.4) | 1128 (74.8) |
| Diabetes | 585 (39.0) | 574 (38.0) |
| Requiring insulin | 104 (6.9) | 98 (6.5) |
| Current smoker | 399 (26.6) | 311 (20.6) |
| Anemiac | 121 (8.1) | 142 (9.4) |
| Heart failure | 115 (7.7) | 107 (7.1) |
| Cancer | 114 (7.6) | 142 (9.4) |
| Peripheral artery disease | 96 (6.4) | 100 (6.6) |
| Severe chronic kidney diseased | 82 (5.5) | 84 (5.6) |
| Estimated glomerular filtration rate <30 mL/min/1.73 m2 without dialysis | 30 (2.0) | 34 (2.3) |
| Dialysis | 52 (3.5) | 50 (3.3) |
| Chronic obstructive pulmonary disease | 40 (2.7) | 44 (2.9) |
| Atrial fibrillation | 35 (2.3) | 22 (1.5) |
| Prior bleeding events | 19 (1.3) | 28 (1.9) |
| Thrombocytopeniae | 15 (1.0) | 16 (1.1) |
| Cirrhosis | 6 (0.4) | 4 (0.3) |
| Left ventricular ejection fraction, mean (SD), % | 59.8 (10.2) | 59.7 (10.6) |
| <40, No. (%) | 59/1368 (4.3) | 56/1395 (4.0) |
| PARIS thrombotic risk score, median (IQR)f | 3 (1-4) | 2 (2-4) |
| High (≥5), No. (%) | 211 (14.1) | 215 (14.3) |
| Intermediate (3-4), No. (%) | 560 (37.3) | 536 (35.5) |
| Low (0-2), No. (%) | 729 (48.6) | 758 (50.2) |
| PARIS bleeding risk score, median (IQR)f | 5 (3-7) | 5 (3-7) |
| High (≥8), No. (%) | 302 (20.1) | 291 (19.3) |
| Intermediate (4-7), No. (%) | 757 (50.5) | 801 (53.1) |
| Low (0-3), No. (%) | 441 (29.4) | 417 (27.6) |
| CREDO-Kyoto thrombotic risk score, median (IQR)g | 1 (0-2) | 1 (0-2) |
| High (≥4), No. (%) | 113 (7.5) | 122 (8.1) |
| Intermediate (2-3), No. (%) | 318 (21.2) | 358 (23.7) |
| Low (0-1), No. (%) | 1069 (71.3) | 1029 (68.2) |
| CREDO-Kyoto bleeding risk score, median (IQR)g | 0 (0-1) | 0 (0-1) |
| High (≥3), No. (%) | 106 (7.1) | 112 (7.4) |
| Intermediate (1-2), No. (%) | 398 (26.5) | 401 (26.6) |
| Low (0), No. (%) | 996 (66.4) | 996 (66.0) |
| Procedural characteristics | ||
| Radial approach, No. (%) | 1232 (82.1) | 1264 (83.8) |
| Femoral approach, No. (%) | 202 (13.5) | 180 (11.9) |
| Invasive fractional flow reserve, No. (%)h | 213 (14.2) | 202 (13.4) |
| No. of target lesions, mean (SD) | 1.1 (0.4) | 1.1 (0.4) |
| Target lesion location, No. (%) | ||
| Left main coronary artery | 43 (2.9) | 37 (2.5) |
| Left anterior descending artery | 828 (55.2) | 854 (56.6) |
| Left circumflex coronary artery | 268 (17.9) | 305 (20.2) |
| Right coronary artery | 436 (29.1) | 410 (27.2) |
| Bypass graft | 3 (0.2) | 3 (0.2) |
| Chronic total occlusion, No. (%) | 55 (3.7) | 67 (4.4) |
| Bifurcation lesion, No. (%) | 376 (25.1) | 393 (26.0) |
| ≥2 Target vessels, No. (%) | 100 (6.7) | 116 (7.7) |
| Use of intravascular ultrasound, No. (%) | 1276 (85.1) | 1280 (84.8) |
| Use of optical coherence tomography, No. (%) | 210 (14.0) | 233 (15.4) |
| No. of implanted stents, mean (SD) | 1.3 (0.5) | 1.3 (0.6) |
| Minimal stent diameter, mean (SD), mm | 2.98 (0.49) | 2.96 (0.48) |
| <3.0, No. (%) | 610 (40.7) | 627 (41.6) |
| Total stent length, mean (SD), mm | 30.3 (16.7) | 30.5 (16.8) |
| ≥28, No. (%) | 742 (49.5) | 787 (52.2) |
| Medications at discharge, No. (%) | ||
| Aspirin | 1497 (99.8) | 1509 (100) |
| P2Y12 receptor blockers | 1499 (99.9) | 1508 (99.9) |
| Clopidogrel | 903 (60.2) | 949 (62.9) |
| Prasugrel | 594 (39.6) | 557 (37.0) |
| Anticoagulants | 7 (0.5) | 6 (0.4) |
| Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers | 934 (62.3) | 939 (62.2) |
| β-blockers | 672 (44.8) | 643 (42.6) |
| Statins | 1318 (87.9) | 1318 (87.3) |
| Proton pump inhibitors | 1190 (79.3) | 1193 (79.1) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CREDO-Kyoto, Coronary Revascularization Demonstrating Outcome Study in Kyoto; DAPT, dual antiplatelet therapy; IQR, interquartile range; PARIS, Patterns of Non-Adherence to Anti-Platelet Regimen in Stented Patients.
Acute coronary syndrome was defined as myocardial infarction within 7 days or unstable angina.
Unstable angina was defined as Braunwald classification I to III, without confirmation of any biomarker elevation.
Anemia was defined as a preprocedural hemoglobin level less than 11 g/dL in both men and women.
Severe chronic kidney disease was defined as a preprocedural estimated glomerular filtration rate less than 30 mL/min/1.73 m2 or receipt of maintenance dialysis. Preprocedural creatinine data were missing for 10 patients. Two of these patients who were undergoing dialysis were included in severe chronic kidney disease, while the other 8 patients were regarded as not having severe chronic kidney disease.
Thrombocytopenia was defined as a preprocedural platelet count less than 100×109/L.
The PARIS thrombotic risk score ranges from 0 to 12 and is categorized as low (0-2), intermediate (3-4), and high (≥5) thrombotic risk. The PARIS bleeding risk score ranges from 0 to 15 and is categorized as low (0-3), intermediate (4-7), and high (≥8) bleeding risk.
The CREDO-Kyoto thrombotic risk score ranges from 0 to 12 and is categorized as low (0-1), intermediate (2-3), and high (≥4) thrombotic risk. The CREDO-Kyoto bleeding risk score ranges from 0 to 11 and is categorized as low (0), intermediate (1 or 2), and high (≥3) bleeding risk.
Invasive fractional flow reserve by intracoronary flow wire, not by computed tomography.